BIOMAT Database Logo BIOMAT Database Logo

Decreased ovarian response to human menopausal gonadotropin caused by subcutaneously administered gonadotropin-releasing hormone agonist. 1987

R B Barnes, and A Scommegna, and J R Schreiber

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008596 Menotropins Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations. Gonadotropins, Human Menopausal,Human Menopausal Gonadotropin,CP-89044,CP-90033,HMG Ferring,HMG Lepori,HMG Massone,Humegon,Menogon,Menopur,Menotrophin,Normegon,ORG-31338,Pergonal,Pergonal-500,CP 89044,CP 90033,CP89044,CP90033,Gonadotropin, Human Menopausal,Human Menopausal Gonadotropins,Lepori, HMG,Menopausal Gonadotropin, Human,ORG 31338,ORG31338,Pergonal 500,Pergonal500
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical
D016729 Leuprolide A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. Leuprorelin,A-43818,Enantone,Leuprolide Acetate,Leuprolide Monoacetate,Leuprolide, (DL-Leu)-Isomer,Leuprolide, (L-Leu)-Isomer,Lupron,TAP-144,A 43818,A43818,Acetate, Leuprolide,Monoacetate, Leuprolide,TAP 144,TAP144

Related Publications

R B Barnes, and A Scommegna, and J R Schreiber
Ovarian response to human menopausal gonadotropin after therapy with the gonadotropin-releasing hormone agonist leuprolide.
February 1988, American journal of obstetrics and gynecology,
R B Barnes, and A Scommegna, and J R Schreiber
Failure to improve ovarian response by combined gonadotropin-releasing hormone agonist and gonadotropin therapy.
January 1990, Gynecologic and obstetric investigation,
R B Barnes, and A Scommegna, and J R Schreiber
The response of patients with polycystic ovarian disease to human menopausal gonadotropin therapy after ovarian electrocautery or a luteinizing hormone-releasing hormone agonist.
February 1992, Fertility and sterility,
R B Barnes, and A Scommegna, and J R Schreiber
Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression.
January 1990, Fertility and sterility,
R B Barnes, and A Scommegna, and J R Schreiber
Delayed ovarian response in oligomenorrheic women using gonadotropin-releasing hormone agonist.
January 1991, International journal of fertility,
R B Barnes, and A Scommegna, and J R Schreiber
Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
June 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
R B Barnes, and A Scommegna, and J R Schreiber
Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
June 1992, Journal of assisted reproduction and genetics,
R B Barnes, and A Scommegna, and J R Schreiber
Testicular secretion after pulsatile human menopausal gonadotropin therapy in gonadotropin-releasing hormone agonist desensitized dysspermic men.
July 1994, Fertility and sterility,
R B Barnes, and A Scommegna, and J R Schreiber
Binding of gonadotropin releasing hormone agonist to rat ovarian granulosa cells.
December 1980, Life sciences,
R B Barnes, and A Scommegna, and J R Schreiber
Successful treatment of long-term unexplained infertility with gonadotropin-releasing hormone agonist analogue and human menopausal gonadotropin.
January 1990, Acta obstetricia et gynecologica Scandinavica,
Copied contents to your clipboard!